SU1734756A1 - Method for treating acute viral hepatitis - Google Patents

Abstract

This invention relates to medicine, in particular to hepatology and the treatment of infectious diseases in children. The goal is to reduce the time of treatment in children with an average form of the disease due to the hepatoprotective effect. For this purpose, enterodesis is administered in a dose of 0.3 to 2-3 doses. The use of the method in 54 children with acute viral hepatitis, unlike other methods of detoxification, allowed to achieve rapid regression of hepatomegaly, jaundice and normalization of the activity of aminotransferase, reducing the amount of transfusion therapy needed by 5 times. Thus, enterodez is offered as the drug of choice for oral detoxification in patients with acute viral hepatitis. 2 tab. w Ё

Description

This invention relates to medicine, in particular to hepatology and the treatment of infectious diseases in children.

The purpose of the invention is to reduce the duration of treatment in children with an average form of the disease due to the hepatoprotective effect.

The method is carried out as follows.

Enterodesis in an amount of 5 g is dissolved in 100 ml of a 5% glucose solution and administered orally between meals at the rate of 0.3 g of the preparation per 1 kg of body weight per day for 7 days.

PRI me R 1. Sick M., 6 years. He was admitted with a diagnosis of viral hepatitis, moderate severity. The preicteric period proceeded according to a mixed variant, lasted 5 days. Complaints of severe weakness, nausea, pain in the right hypochondrium. Ill in la, sleepy. Jaundice of considerable intensity. In the lungs, vesicular respiration. Pulse - 100 beats / min. Heart sounds are loud. The tongue is coated with white bloom. Liver +2.5 +3.5 + average / 3, compacted, painful. Spleen at the costal arch. Urine is dark, stools discolored. Er 1,5x1012 / l; L 9.2x10%; ESR 17 mm / h. Total bilirubin 205.2 µmol / l; Al AT 1335 nmol / s "l, thymol sample 19.0. In the serum HBS Hell is not detected.

Taking into account intoxication syndrome, jaundice intensity, liver enlargement and tenderness, biochemical analyzes, viral hepatitis A was diagnosed.

Conventional therapy (diet, bed rest, drinking 5% glucose solution, multivitamins) without pronounced effect. From the third day of hospitalization, enterodesis, 2.5 g 3 times a day in 50 ml of 5% glucose solution for 7 days was started.

After 2 days of enterodesis (jaundice 7 days), the patient's condition improved: wils appetite, pain in the right

VI CJ XJ SL O

hypochondrium, nausea. Bilirubin decreased to 102.6 µmol / l, AlAT 1112 nmol / s l. By day 13 of jaundice, total bilirubin decreased to 41.0 µmol / L, AlAT 556 nmol / s "l. In the future, the patient was carried out only basic therapy.

The course of the disease was favorable. By the 16th day of treatment in the hospital, the size of the liver normalized, the level of bilirubin and the activity of enzymes decreased to the norm. The child was discharged in a satisfactory condition with complete recovery. Bed day was 17 days.

When examined through the month, the condition of the girl is good. No complaints. The liver is not enlarged. Bilirubin and ALT activity are normal.

PRI mme R 2. Patient G., 5 years. He was admitted with a diagnosis of viral hepatitis. The prepuruscid period proceeded according to a mixed variant, lasted for 6 days. Before the present illness was in the children's sanatorium, where he was given parenteral interventions. On admission, the state of moderate severity was marked by weakness, arousal, and fussy movements. Severe yellowness of the skin and sclera. In the lungs, vesicular respiration. Pulse 88 beats / min. Heart sounds are loud. The tongue is coated with white bloom. Liver +2.0 +2.5 +1.5 cm, compacted, painful. The spleen is not enlarged. Urine is full. The chair is discolored. Total bilirubin 95.7 μmol / l, AlAT 1590 nmol / s-l, thymol test - 8.0. Er -4.1x1012 / l; L-5.3x10%, VOE 11 mm / h. HBsAg was detected in serum. Clinical diagnosis: viral hepatitis B moderate.

Treatment: conventional diet, bed rest, drinking 5% glucose solution, multivitamins without a pronounced effect. On the third day of the intake, enterodesis, 2.5 g, 3 times a day in 50 ml of 5% glucose solution was started during

7 days. After 3 days from the start of the drug administration (6th day of jaundice), the patient's condition improved significantly. Appetite was restored, intoxication disappeared, bilirubin decreased to 27.0 µmol / l, AlAT 727 nmol / s-l, the course of the disease was favorable. On day 16, bilirubin was normalized from the intake - 13.6 µmol / L, HBsAg secretion stopped. Assets-

AlAT was normalized to 88 nmol / sl by day 30. The list was reduced to 0.5 cm. When examined through the month c - liver of normal size, the biochemical parameters are normal. HBsAg is not detectable.

The method was tested in 54 children with acute viral hepatitis A and B. As a result of treatment with enterodesis, not only the reduction in the duration of intoxication was halved, but also a more rapid regression

hepatomegaly, jaundice, and increased activity of aminotransferases, both in comparison with the placebo group and when using detoxification by intravenous administration of a 10% aqueous solution of hemodez (Table 1) or enterosorption with carbon sorbent SKN-3M (Table 2). The method allowed to reduce the amount of necessary transfusion therapy by 5 times while reducing the duration of treatment for the disease. Thus, the conducted research allows recommending enterodesis as the drug of choice for enterosorption in children with acute viral hepatitis.

Claims (1)

The invention The method of treating acute viral hepatitis, including oral detoxification with the help of enterosorbents, is due to the fact that in order to shorten the treatment time due to the hepatoprotective effect in children with an average form of the disease, enterodesis is administered at a dose of 0.3 g / kg / day. Table Note.— Significant differences with the placebo group. b - significant differences between groups of enterodesis and transfusion therapy. Table 2